27 results about "Colistin" patented technology

A polyclonal antibody composition specifically binds the pTonB epitope (SEQ ID NO: 11) from Acinetobacter baumannii and is elicited by immunization with a multi-epitope antigen comprising thioredoxin leader, rigid linker, and kernels including SEQ ID NOs: 6, 7, 11, 12, and 8. These antibodies enhance opsonophagocytic killing of A. baumannii Ci79 via classical complement activation and Fey receptor-mediated phagocytosis by bone marrow-derived macrophages. Absorption of pTonB-specific antibodies reduces killing by >70%, confirming epitope dominance. Passive transfer of the composition protects >60% of mice in a lethal intranasal challenge model. Pharmaceutical compositions, treatment methods (alone or with antibiotics like colistin), prophylactic uses, diagnostic kits, and polyclonal compositions are disclosed for combating multidrug-resistant A. baumannii infections.

The present application relates to the field of biomedicine technology, and in particular to the use of an antithrombotic small molecule compound BPTU (CAS No. 870544-59-5) as a colistin adjuvant for synergistic anti-Gram-negative bacteria, wherein the antithrombotic small molecule compound BPTU comprises a compound as shown in Formula I; the use of the antithrombotic small molecule compound BPTU as a colistin adjuvant for synergistic anti-Gram-negative bacteria, BPTU and colistin have a synergistic antibacterial effect on Gram-negative bacteria, the outer membrane of Gram-negative bacteria can act as a drug barrier, and colistin has membrane-breaking activity, and colistin breaks the barrier effect of the cell membrane to assist BPTU in entering the cell to exert its antibacterial activity. Therefore, the combined use of the antithrombotic small molecule compound BPTU and colistin has broad application prospects in the treatment of Gram-negative bacteria.

The present invention relates to a method for treating Gram-negative bacteria that are resistant to colistin (MIC > 50 mg / mL), an antibacterial compound, excluding those of the genera Burkholderia, Proteus, and Serratia, comprising contacting the bacteria with an aqueous pharmaceutical composition containing a rose bengal (RB) compound of formula I, dissolved or dispersed at a concentration of about 0.01 to about 15 mg / mL, and irradiating the contacted bacteria with light of a wavelength of about 500 nm to about 600 nm for a period of about 1 to about 10 minutes, at a concentration of about 16 to about 160 J / cm². 2 The aim is to create a method that involves obtaining a certain amount of light to treat and kill irradiated bacteria. [Formula 1] JPEG2026511692000028.jpg5864 (where X, R 1 , R 2 (and M+ are defined herein)

Colistin is an important last-resort antibiotic, but its production involves significant challenges due to the presence of impurities resulting from various analogs and the limited number of native producers. In response, disclosed are mutant Paenibacillus bacteria that produce Colicin A more efficiently and / or Colicin A that is of higher purity and / or has a cleaner metabolite background. The disclosed mutant bacteria are genetically engineered to inactivate expression of one or more biosynthetic gene clusters (BGCs), increase expression of one or more other BCGs, and / or increase expression of one or more L-DABA pathway genes.

The application discloses application of BMS-833923 and derivatives thereof and a medicine, and belongs to the technical field of antibiotics. The BMS-833923 and the derivatives thereof can be used as colistin adjuvants to jointly inhibit or eliminate gram-negative bacteria, and can also independently inhibit or eliminate gram-positive bacteria. The gram-negative bacteria can include at least one of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, pan-drug-resistant strains BAA-1800, BAA-1794 and BAA-1792, and the gram-positive bacteria can include at least one of Staphylococcus aureus and Bacillus subtilis. By taking the BMS-833923 and the derivatives thereof as adjuvants of colistin, the therapeutic index of the colistin can be effectively expanded, and lower, non-toxic doses of the colistin can be used in clinical treatment of effective treatment of drug-resistant bacterial infections.

Colistin is an important last-resort antibiotic, but its production involves significant challenges due to the presence of impurities resulting from various analogs and the limited number of native producers. In response, disclosed are mutant Paenibacillus bacteria that produce Colicin A more efficiently and / or Colicin A that is of higher purity and / or has a cleaner metabolite background. The disclosed mutant bacteria are genetically engineered to inactivate expression of one or more biosynthetic gene clusters (BGCs), increase expression of one or more other BCGs, and / or increase expression of one or more L-DABA pathway genes.

The invention discloses an application of liquiritigenin in preparation of a bactericide or an antibiotic synergist. The invention discloses the synergistic effect, the antibacterial property and the synergistic mechanism of liquiritigenin on colistin and the potential value of in-vivo combined application of liquiritigenin. On the basis, a feasible treatment scheme is provided to cope with the increasingly aggravated drug resistance problem, the use curative effect of the colistin is effectively enhanced, and the clinical service life of the colistin is prolonged. The possibility that liquiritigenin is used as a colistin synergist to resist infection of multi-drug-resistant pathogenic bacteria is reduced. The liquiritigenin can reduce the minimum inhibitory concentration of the colistin to drug-resistant gram-negative bacteria by 16 times, and the antibacterial activity of the colistin is greatly improved.

This invention relates to the field of biochemical technology, and particularly to highly specific haptens of polymyxin B and colistin, artificial antigens, their preparation methods, and applications. The haptens have structures as shown in Formula I or Formula II. The applications include: (1) preparing specific antibodies against polymyxin B or colistin; (2) detecting specific antibodies against polymyxin B or colistin; and (3) preparing reagents for detecting specific antibodies against polymyxin B or colistin. This invention further provides artificial antigens obtained by conjugating the haptens with carrier proteins. Using the artificial antigens provided by this invention as immunogens to immunize experimental animals, highly specific and sensitive antiserum can be prepared, which can then be used to extract and prepare polyclonal antibodies. These methods can be used to establish highly specific, highly sensitive, simple, and rapid detection methods for polymyxin B and colistin, and have significant application value.

The invention relates to application of Colistin in preparation of a medicine for treating and preventing acute respiratory distress syndrome, and relates to the technical field of medicines. The Colistin effectively inhibits calcium ion cell influx by inhibiting a mechanical sensitive channel of Piezo1 protein, further prevents and reduces pathological changes such as pulmonary hemorrhage, neutrophil infiltration, pulmonary capillary hyperemia and interval thickening in the ARDS disease, plays an important role in preventing or treating the acute respiratory distress syndrome, and has a huge application prospect.

The invention belongs to the technical field of bacteria detection, and discloses an analysis method for detecting colistin in bacteria. The method comprises the following steps: firstly, centrifugally washing bacterial suspension incubated by sub-bacteriostasis colistin, and repeatedly freezing and thawing by adopting liquid nitrogen, so that bacterial cells are cracked; placing the split thalli in an acidic solution, and hydrolyzing at 60-120 DEG C in a protective atmosphere to obtain 2, 4-diaminobutyric acid; adjusting the pH to be neutral by using an alkaline solution to obtain hydrolysate; adding a derivatization buffer solution and a derivatization agent chloroformic acid-9-fluorenyl methyl ester into the hydrolysate, reacting at 20-80 DEG C to obtain a derivatization reaction solution, and treating to obtain filtrate; and separating the filtrate through a C8 reversed-phase chromatographic column, determining by selecting a fluorescence detector, and qualitatively and quantitatively analyzing the colistin in the bacteria by adopting a standard addition method, so that the colistin in the bacteria can be detected. According to the method, the colistin in the bacteria is detected by using a high performance liquid chromatography-fluorescence method, and a technical support is provided for exploring an antibacterial action mechanism of the colistin and a drug resistance mechanism of the bacteria.

The present invention relates to the synergic association of colistin and N-acetylcysteine (NAC) for the treatment and eradication of mature biofilm-associated infections by P. aeruginosa. In particular the synergic association of colistin and NAC is useful for the treatment and eradication of P. aeruginosa infections in patients suffering from chronic lung diseases and recurrent P. aeruginosa infections.

The invention discloses a fermentation method for reducing non-methane hydrocarbon in colistin E fermentation tail gas, and belongs to the technical field of biochemical engineering. The method specifically comprises the following steps: A, inoculating cultured seed liquid into a fermentation culture medium for fermentation; b, supplementing bibenzylpyridine in the fermentation process; c, stopping fermentation after fermenting for a period of time; in the step A, the inoculation amount is 1-20%, and a fermentation medium comprises the following components in parts by mass / volume (W / V): 1-10 parts of corn starch, 0.01-1 part of glucose, 1-10 parts of bean flour, 0.01-2 parts of monopotassium phosphate, 0.01-10 parts of ammonium sulfate, 0-1 part of sodium chloride, 0-1 part of magnesium sulfate, 0.01-5 parts of calcium carbonate and 0.001-1 part of liquid defoaming agent. The key technology of the invention is as follows: cultured seed liquid is inoculated into a fermentation medium for fermentation, bibenzylpyridine is supplemented in the fermentation process, and fermentation is stopped after fermentation is performed for a period of time. Wherein a small amount of bibenzylpyridine is supplemented, so that the level of non-methane total hydrocarbon can be effectively reduced, and meanwhile, the yield is favorably increased.

The present invention provides antibiotic combination therapies for treating Acinetobacter baumannii infection in a subject. These combination therapies comprise rifudine and a second antibiotic such as colistin and cefdinir.

The invention relates to the technical field of biological medicine, in particular to application of an antithrombotic small molecule compound BPTU (CAS number 870544-59-5) as a colistin adjuvant to synergistically resist gram-negative bacteria, and the antithrombotic small molecule compound BPTU comprises a compound as shown in a formula I; according to the application of the antithrombotic small molecule compound BPTU serving as the colistin adjuvant to synergistically resist gram-negative bacteria, the BPTU and the colistin have a synergistic antibacterial effect on the gram-negative bacteria, an extracellular membrane of the gram-negative bacteria can play a role in a drug barrier, the colistin has membrane breaking activity, the barrier effect of the cell membrane is broken by the colistin, and the effect of the drug barrier is improved. The antithrombotic micromolecular compound BPTU and colistin are combined to assist the BPTU to enter cells to exert antibacterial activity, so that the antithrombotic micromolecular compound BPTU and colistin are combined for medication and have a wide application prospect in treatment of gram-negative bacteria.

Described herein are compositions, methods, and kits for detecting antibiotic resistance genes in a sample, such as a wound swab. One embodiment described herein is primer pairs and probes for individual or multiplex polymerase chain reaction (PCR) based assays for the detection of one or more antibiotic resistance gene targets comprising resistance to molecularly characterized extended-spectrum β-lactamases (MESBLs); extended-spectrum β-lactamases (ESBLs); carbapenemase; AmpC β-lactamase; β-lactamase; lincosamide, macrolide, streptogramin; trimethoprim; macrolides; methicillin; colistin; sulfonamide; tetracycline; vancomycin; nitroimidazole; quinolone; or aminoglycoside.

The present invention contemplates a method for treating gram-negative bacteria other than the genus Burkholderia, Proteus and Serratia, said gram-negative bacteria also exhibiting drug resistance (MIC > = 50 mg / mL) against the bacterial compound colistin, said gram-negative bacteria also exhibiting drug resistance (MIC > = 50 mg / mL) against the bacterial compound colistin, such as colistin, colistin, colistin, colistin, colistin, colistin, colistin, colistin, colistin, colistin, colistin, colistin and colistin. The method comprises contacting bacteria with an aqueous pharmaceutical composition containing a rose-bengal (RB) compound of the following formula I dissolved or dispersed therein at a concentration of from about 0.01 to about 15 mg / mL, and irradiating those contacted bacteria with light having a wavelength of from about 500 nm to about 600 nm for a period of from about 1 to about 10 minutes to provide a light dose of from about 16 to about 160 J / cm2, treating and killing the irradiated bacteria, wherein X, R1, R2 and M + are defined herein.

The invention relates to the technical field of biological medicine. The invention provides an application of Obtoclax mesylate and / or Nigericin in preparation of an antibiotic sensitizer, wherein the antibiotic comprises colistin. The invention also provides an application of Obtoclax mesylate and / or Nigericin in preparation of the antibiotic sensitizer. The invention further provides an application of the medicine composition of the colistin and the Obtoclax mesylate or the Nigericin in preparation of the medicine for resisting the colistin drug resistance gram-negative bacteria, and the medicine composition of the colistin and the Obtoclax mesylate or the Nigericin can be used for preparing the medicine. According to the technical scheme, the colistin and Obtoclax mesylate or Niguricin are combined for use, so that a synergistic effect is achieved, the MIC value of the colistin for resisting colistin-resistant gram-negative bacteria can be remarkably reduced, and the growth of the gram-negative bacteria is inhibited.

The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and / or treatment of bacterial infections and antibacterial-induced dysfunctions. The compositions of the present invention demonstrate high species-specificity in inhibiting the growth of a small number of bacterial species, and most importantly are effective also against multi drug resistant (MDR) clinical isolate species. Interestingly, one of those combinations pairs a non-antibiotic drug, vanillin, with an antibiotic drug, spectinomycin, to demonstrate a surprisingly strong inhibitory effect on the growth of clinically relevant Gram-negative pathogenic and multi-drug resistant E. coli isolates. A second set of compounds combines the polymyxin colistin with loperamide, a rifamycin, or a macrolide. Importantly, this invention relates to combinations that enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development efforts in order to prevent major side effects of antibacterial strategies. This invention also relates to pharmaceutical combinations useful to prevent an adverse effect on the gut microbiome, induced by the use of antibacterial compounds.

The present invention is directed to novel resistance modifying agents (RMAs) compounds configured to potentiate antibiotic compounds, such as polymyxin antibiotics, including colistin, directed to multi-drug resistance (MDR) gram-negative bacteria.

The application discloses application of sphingosine or its acceptable salt in preparation of a medicine or preparation for killing and / or inhibiting bacteria in and out of organisms. The application discloses application of sphingosine or its acceptable salt in preparation of a medicine for bacterial infectious diseases or preparation of an antibiotic synergist. The application discloses a medicine composition comprising sphingosine and colistin. The application discloses application of the composition in preparation of a medicine or preparation for killing and / or inhibiting bacteria in and out of organisms or preparation of a medicine for bacterial infectious diseases or an antibiotic synergist. The application finds the possibility of sphingosine as the colistin synergist for resisting multiple drug-resistant pathogenic bacterial infection through in-vivo and in-vitro antibacterial tests. The sphingosine can reduce the minimum inhibitory concentration of colistin to drug-resistant gram-negative bacteria by 30 times, greatly improving the antibacterial activity of colistin.

The application discloses a method for improving colistin E wastewater treatment capacity, and belongs to the technical field of wastewater treatment. Specifically, the method comprises the following steps: A, taking activated sludge and placing the activated sludge in a reactor; B, taking colistin E production wastewater with additional cyclic diguanidate, and making the colistin E production wastewater flow through the reactor at a certain organic load. The colistin E production wastewater has a toxic effect on the microorganisms in the activated sludge in many aspects, so that the growth of the microorganisms is inhibited. The cyclic diguanidate is a key regulating factor for synthesizing extracellular matrix, and it can activate a series of genes participating in the synthesis of components such as extracellular polysaccharide and protein, so that the microorganisms can produce a large amount of extracellular matrix. The extracellular matrix is a main component of a biofilm, and can provide protection and a stable living environment for the microorganisms. The experiment proves that the colistin E production wastewater with additional cyclic diguanidate can effectively improve the wastewater treatment capacity.

The present invention provides antibiotic combination therapies for treating Acinetobacter baumannii infections in a subject. These combination therapies comprise rifabutin and a second antibiotic such as colistin and cefiderocol.

The invention discloses a lactic acid bacteria bacteriostatic composition, a bacteriostatic effervescent tablet and application. The lactic acid bacteria bacteriostatic composition is prepared from the following raw materials in parts by weight: 15 to 30 parts of lactic acid bacteria powder, 10 to 16 parts of colistin, 5 to 8 parts of niclosamide, 0.8 to 1 part of polyhexamethylene biguanide hydrochloride and 39 to 66 parts of auxiliaries. The traditional Chinese medicine composition has obvious anti-inflammatory and bacteriostatic effects, has a remarkable treatment effect on vaginitis, can increase the permeability of outer membranes of germs, destroy the integrity of cell membranes and inhibit the activity of an efflux pump at the same time, drugs cannot be discharged by the efflux pump, the accumulation concentration of intracellular drugs is increased, bacterial death is caused, and a large amount of active oxygen of the germs is induced to be synthesized, so that the effect of treating the vaginitis is achieved. Oxidative damage of thalli is accelerated, normal physiological activities are affected, bacterial death is caused, and the relative expression quantity of inflammatory factors can be reduced, so that the antibacterial activity is enhanced.

The invention discloses an application of Incyclinide and colistin in preparation of a bactericidal drug for enterobacteriaceae bacteria carrying a mcr (mcr) gene. Incyclinide (Ini) is a chemically modified tetracycline derivative, the invention proves that Ini can recover the bactericidal effect of colistin on enterobacteriaceae bacteria carrying mcr genes in vitro and in animal models, and mechanism analysis shows that Ini recovers the drug effect of colistin by inhibiting lipid A modification, inducing oxidative damage and dissipating proton power (PMF). As a colistin adjuvant, Ini has huge potential in the aspect of resisting enterobacteriaceae bacteria carrying mcr genes.

This invention discloses a fermented Sophora japonica flower extract for enhancing the efficacy of colistin, its preparation method, and its application. The preparation method of the fermented Sophora japonica flower extract includes the following steps: inoculating Aspergillus niger into a solid fermentation medium containing Sophora japonica flowers for fermentation to obtain a fermented product; separating the fermented product to obtain the fermented Sophora japonica flower extract. This fermented Sophora japonica flower extract can enhance the inhibitory effect of colistin on Salmonella (especially Salmonella pullorum), helping to reduce antibiotic use and combat the growth of drug resistance.

The invention discloses a method for improving colistin E wastewater treatment capacity, and belongs to the technical field of wastewater treatment. The method specifically comprises the following steps: A, putting activated sludge into a reactor; and B, taking the colistin E production wastewater additionally added with cyclic diguanylic acid to flow through the reactor at a certain organic load. The colistin E production wastewater has a multi-aspect toxic effect on microorganisms in activated sludge, so that the growth of the microorganisms is inhibited, and cyclic diguanylate is a key regulatory factor for synthesizing an extracellular matrix and can activate a series of genes participating in the synthesis of components such as exopolysaccharides and proteins, so that the microorganisms can generate a large amount of extracellular matrix, and the growth of the microorganisms is inhibited. The extracellular matrixes are main components forming the biological membrane and can provide a protective and stable living environment for microorganisms. Experiments prove that the cyclic diguanylate is additionally added into the colistin E production wastewater, so that the wastewater treatment capacity can be effectively improved.